-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
DOC delivered mixed Q1 2026 results with revenue up 7.1% Y/Y to $753M and rental revenue of $739M (+7.5%) exceeding consensus by $46M, though FFO per share declined to $0.45 from $0.46 but beat estimates by $0.02. The successful Janus Living IPO generated $880M in proceeds and created a $6.9B market cap senior housing platform, validating management's value unlock strategy while DOC retains 81.6% ownership. Updated 2026 guidance reflects the IPO impact, with EPS raised to $0.46-$0.50 while FFO lowered to $1.68-$1.72 due to lost management fees. Same-store NOI was flat with Senior Housing strength (+13.8%) offset by Lab struggles (-7.2%). Occupancy pressures continued with Lab down 740 bps Y/Y to 90.4% and Outpatient Medical down 70 bps to 91.8%. DOC repurchased $100M in shares. We believe Outpatient Medical occupancy will improve but see Lab vacancy rates increasing through Q3 2026. We see persistent biotech funding challenges limiting Lab upside through 1H 2027.